Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|3|193-196

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.3, 2015-03, pp. : 193-196

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Initial experience with CMC‐544 (inotuzumab ozogamicin) in pediatric patients with relapsed B‐cell acute lymphoblastic leukemia

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 369-372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 371-374

John Wiley & Sons Inc

Access to resources Recommend Favorite

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3612-3621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 89-90

Karger

Access to resources Recommend Favorite